USP Postponing Chapters 795, 797, and 825
Several pharmacy groups appealed guideline revisions.
The Latest Autoimmune Disease Treatment Advances
Psoriasis, MS, Lupus, and RA.
5 Pipeline Drugs to Watch
A look at some of the exciting drugs that could be approved in the coming months.
FDA Approves Jynneos for Smallpox and Monkeypox in Adults
Will be part of the U.S.’s public health emergency medical supplies and pharmaceuticals.
FDA Urged to Expedite Ranitidine Recalls
Online pharmacy that discovered the impurity discontinues sales.
Unique Offerings Increasing Revenue
Some pharmacies are now serving coffee and other refreshments.
Investigational Guillain-Barré Syndrome Treatment Granted FDA Fast Track Designation
Monoclonal antibody for autoimmune and neurodegenerative disorders.
The Growing Problem of Pharmacy Deserts
An estimated 100 million Americans lack good access to pharmacies.
What is a Pharmacy Desert?
Caused by lower income, insurance status, higher prices, poor transportation, long distances.
FDA Encourages OTC Naloxone and Expanded Access at Pharmacies
Approved forms should be considered as options for community distribution.
New Semaglutide Dosage Forms Approved by FDA
Now approved in 7mg and 14 mg tablets.
Patient Services are Crucial to the Economics of Pharmacy
Layoffs highlight increasing jobs problem.
A Look at USP 795, 797, and 800
Loyd Allen, Editor in Chief of the International Journal of Pharmaceutical Compounding, discusses the similarities and differences between three primary chapters of the USP professional practice standards.
The Difference Between 503a and 503b Compounding Pharmacies
Loyd Allen, Editor in Chief of the International Journal of Pharmaceutical Compounding, discusses the roles and limitations of each respective compounding classification.
Challenges and Barriers to 503B Compounding
Ernest P. Gates Jr., president, CEO, Gates Healthcare Associates, lays out some of the biggest hurdles to bulk compounding.
The Importance of Compounding for Personalized Care
Lawrence Maida, proprietor, pharmacist in charge, Maida Pharmacy and Compounding Center, discusses some of the reasons why compounding is vital for keeping healthcare personal.
Compounding Video Roundtable
Fred Gebhart, Drug Topics contributing editor, lays out the history of compounding and introduces three experts in the pharmaceutical compounding field.
Potential Treatment for Traumatic Brain Injury Receives Regenerative Advanced Therapy Designation
Derived from cultured adult bone marrow-derived mesenchymal stem cells that have undergone temporary genetic modification.
New Video Marketing Tools
Ensuring your pharmacy’s video marketing dusts the competition has never been more important.
At a Glance: Asthma Biologics
Obinutuzumab Receives Breakthrough Therapy Designation from FDA
Monoclonal antibody shows potential for lupus nephritis treatment.
Antimicrobial Stewardship: Protecting Global Health
Programs shown to improve patient outcomes, reduce antibiotic resistance, and decrease healthcare costs.
Antibiotic Counseling Pearls for the Community Setting
Vaccinations Are Increasingly Important as Hepatitis A Epidemic Grows
23,600 cases across 29 states since 2016.
FDA Approves First Drug Under Project Orbis
Combination therapy for advance endometrial carcinoma.
Top Challenges in Managing Diabetes
Cost, education, self-monitoring, and more.
Fear Motivates Vaccinations, New Study Finds
Fear, one's faith in the government, and likelihood of exposure are leading factors.
Optimism for AI in Cancer Care
Oncologists recognize the potential of artificial intelligence (AI) in improving the quality of care and patient outcomes according to new research.
New Drug Review: Pretomanid for Highly Drug Resistant Tuberculosis
Indicated as part of a three-drug oral combination.
Oncology Market Remains Robust, Says Report
The 2018 oncology drug market had a record number of new treatments and continued a trend of growth.
